| Sub-Vertical | Primary Challenge | Our Approach |
|---|---|---|
| Pharmaceutical (Large & Specialty) | Complex procurement, formulary positioning, regulatory-aware content requirements | ABM for key account teams, regulatory pathway content, health economics materials |
| Biotech | Stage-gated decisions, investor-influenced priorities, scientific buyer sophistication | Scientific content marketing, partnership ABM for CDMOs and CROs, investor narrative alignment |
| MedTech / Medical Devices | Multi-stakeholder hospital procurement (clinical, procurement, IT, C-suite) | Health economics content, IDN/GPO strategy, clinical champion activation |
| CDMO / CRO | Small universe of high-value pharma partnership targets | Regulatory expertise content, conference ABM, multi-phase partnership development |
| Digital Health | Health system procurement, HIPAA compliance in marketing, clinician adoption | Compliance-aware content, EHR integration content, health IT-specific ABM |
Life sciences buyers are trained to evaluate claims against evidence standards. A pharmaceutical procurement professional, a clinical champion at a hospital system, or a regulatory affairs lead at a biotech company will not be persuaded by generic benefits claims. They need specific, verifiable data: clinical outcomes from peer-reviewed publications, process capability data from qualified manufacturing operations, regulatory track records from actual submission experience.
Life sciences purchases at health systems, pharmaceutical companies, and biotech organisations go through formal procurement processes value analysis committees, vendor qualification, legal review, and often executive approval for significant contracts. Demand generation needs to equip buyers with the materials they need to navigate internal approval processes, not just generate initial interest.
Marketing content in life sciences must comply with relevant regulatory requirements particularly for medical device promotional materials, pharmaceutical commercial content, and health IT claims. Content that makes clinical efficacy claims without proper evidentiary support, or that references regulatory pathways inaccurately, creates compliance risk. All marketing content should be reviewed against applicable regulations (FDA promotional regulations, EU MDR requirements, country-specific pharmaceutical promotion rules).
Life sciences partnerships CDMOs manufacturing clinical and commercial batches, CROs running multi-year clinical programmes, MedTech companies providing long-term hospital service contracts are not transactional. The relationship built during the sales process extends for years. Demand gen and ABM that builds genuine trust and demonstrates deep domain understanding creates better long-term commercial outcomes than volume-based lead generation.
